In Utero Stem Cell Transplantation

Flake, AW; Mr, Harrison; Zanjani, ED

doi:10.1007/978-1-4939-3483-6_17

Cited by 13 publications

(3 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior work has shown that exogenous hematopoietic stem cells (HSCs) and MSCs engraft in the fetal bone marrow after either placental, fetal intravenous, or fetal intraperitoneal administration (Boelig and Flake 2016). To our knowledge, donor MSC engraftment in the host fetal bone marrow after simple intra-amniotic infection had not been described prior to the TRASCET studies mentioned.…”

Section: Donor Mesenchymal Stem Cell Homing After Trascetmentioning

confidence: 98%

Transamniotic Stem Cell Therapy

Lazow

Fauza

2019

Cell Biology and Translational Medicine, Volume 7

View full text Add to dashboard Cite

Section: Donor Mesenchymal Stem Cell Homing After Trascetmentioning

confidence: 98%

Transamniotic Stem Cell Therapy

Lazow

Fauza

2019

Cell Biology and Translational Medicine, Volume 7

View full text Add to dashboard Cite

“…Therefore, other strategies to improve engraftment are needed. Some potential strategies proposed have included RNA interferences, antibodies that target the fetal hematopoietic progenitors, targeted delivery of proapoptotic peptides to host stem cells, treatment of gene therapies with growth factors, 98 and adding enriched bone marrow to treatments. 99 PIDs have been at the forefront of many cutting-edge treatments, such as HSCT and postnatal gene therapies.…”

Section: In Utero Gene Therapymentioning

confidence: 99%

In Utero Gene Therapy for Primary Immunodeficiencies

Mardy

Norton

2021

Clinical Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Primary immunodeficiencies (PIDs) have become a prime target for gene therapy given the morbidity, mortality, and the single gene etiology. Given that outcomes are better the earlier gene therapy is implemented, it is possible that fetal gene therapy may be an important future direction for the treatment of PIDs. In this chapter, the current treatments available for several PIDs will be reviewed, as well as the history and current status of gene therapy for PIDs. The possibility of in utero gene therapy as a possibility will then be discussed.

show abstract

“…Both these cell types develop within different hematopoietic sites throughout ontogeny, suggesting a close interplay between the two systems (22). Exogenous HSC and MSC engraftment to the fetal bone marrow has long been reported after administration of these cells through the placenta, intravenously in the developing embryo or fetus, or intraperitoneally in the fetus (23). To my knowledge, fetal bone marrow engraftment of donor MSCs after plain delivery into the amniotic cavity was yet to be described until these recent studies.…”

Section: Donor Msc Fate After Trascetmentioning

confidence: 99%

Transamniotic stem cell therapy: a novel strategy for the prenatal management of congenital anomalies

Fauza

2017

Pediatr Res

View full text Add to dashboard Cite

Transamniotic stem cell therapy, or TRASCET, is an emerging therapeutic concept for the management of congenital anomalies based on the augmentation of the biological role of select populations of stem cells that already occur in the amniotic fluid, for targeted therapeutic benefit. Amniotic fluid-derived mesenchymal stem cells (afMSCs) have a central role in the enhanced ability of the fetus to repair tissue damage. This germane recent finding constitutes the biological foundation for the use of afMSCs in TRASCET. It has been shown experimentally that simple intra-amniotic delivery of afMSCs in large numbers can either elicit the repair, or significantly mitigate the effects associated with major congenital anomalies by boosting the activity that these cells normally have. For example, TRASCET can induce partial or complete coverage of experimental spina bifida by promoting the local formation of host-derived skin, thus protecting the spinal cord from further damage. In another example, it can significantly alleviate the bowel damage associated with gastroschisis, one of the most common major abdominal wall defects. Other applications involving different congenital anomalies and/or other stem cells present in the amniotic fluid in diseased pregnancies are currently under investigation in this freshly evolving facet of fetal stem cell therapy.

show abstract

In Utero Stem Cell Transplantation

Cited by 13 publications

References 114 publications

Transamniotic Stem Cell Therapy

Transamniotic Stem Cell Therapy

In Utero Gene Therapy for Primary Immunodeficiencies

Transamniotic stem cell therapy: a novel strategy for the prenatal management of congenital anomalies

Contact Info

Product

Resources

About